Key Points
- CEO Sujal Patel bought 25,000 shares on March 4 at an average price of $2.61 (total $65,250), increasing his stake to 10,366,721 shares valued at about $27.06 million (a 0.24% ownership increase).
- Shares traded at $2.49 mid-day (down $0.13) with a 52-week range of $0.62–$3.08, a market cap of roughly $315.13 million and a negative PE of -5.30; the company reported Q results of ($0.11) EPS, beating estimates of ($0.14).
- Analyst sentiment is mixed—Guggenheim lifted its target to $4 and rated the stock "buy" while Weiss Ratings kept a "sell (d-)", leaving MarketBeat's average rating at "Hold" with an average price target of $4.00; institutional investors own about 50.7% of the shares.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal Patel purchased 25,000 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was bought at an average price of $2.61 per share, with a total value of $65,250.00. Following the acquisition, the chief executive officer owned 10,366,721 shares in the company, valued at $27,057,141.81. This trade represents a 0.24% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Nautilus Biotechnology Stock Performance
Shares of NASDAQ NAUT traded down $0.13 during midday trading on Thursday, reaching $2.49. 117,364 shares of the company's stock were exchanged, compared to its average volume of 217,906. Nautilus Biotechnology, Inc. has a 52-week low of $0.62 and a 52-week high of $3.08. The business's fifty day moving average price is $2.19 and its two-hundred day moving average price is $1.62. The stock has a market capitalization of $315.13 million, a PE ratio of -5.30 and a beta of 1.45.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. Analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Nautilus Biotechnology
Large investors have recently bought and sold shares of the business. Virtu Financial LLC boosted its stake in Nautilus Biotechnology by 19.6% in the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company's stock valued at $46,000 after acquiring an additional 3,849 shares during the period. Millennium Management LLC boosted its position in Nautilus Biotechnology by 5.4% during the 4th quarter. Millennium Management LLC now owns 1,019,996 shares of the company's stock valued at $1,989,000 after purchasing an additional 52,448 shares during the period. Bridgeway Capital Management LLC grew its stake in Nautilus Biotechnology by 4.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company's stock worth $254,000 after buying an additional 5,000 shares during the last quarter. Captrust Financial Advisors bought a new position in Nautilus Biotechnology during the 4th quarter worth $66,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Nautilus Biotechnology in the fourth quarter worth $204,000. Institutional investors own 50.71% of the company's stock.
Analysts Set New Price Targets
NAUT has been the subject of several recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. Guggenheim lifted their price target on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Finally, Wall Street Zen upgraded Nautilus Biotechnology from a "sell" rating to a "hold" rating in a research note on Tuesday, November 18th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $4.00.
View Our Latest Report on Nautilus Biotechnology
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.
Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
